"Ascendis Pharma partners with Frazier Life Sciences, RA Capital Management, venBio, and HealthQuest Capital to launch ophthalmology company Eyconis. Eyconis wi
announced Monday the U.S. Food and Drug Administration identified deficiencies in the company s application for a gland treatment. Meanwhile, ASND stock…
announced Monday the U.S. Food and Drug Administration identified deficiencies in the company s application for a gland treatment. Meanwhile, ASND stock…
Ascendis Pharma (ASND) Reports Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The FDA gave a thumbs up to Ascendis Pharma’s long-acting growth hormone lonapegsomatropin-tcgd on Wednesday. Now christened Skytrofa, the drug is the first once-weekly therapy for pediatric growth hormone disorder, but a rival from Pfizer is nearing the finish line.